N-(5-氨基-2-甲氧基苯基)乙酰胺 | 64353-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(5-氨基-2-甲氧基苯基)乙酰胺
• 英文名称: N-(5-amino-2-methoxyphenyl)-acetamide
• 英文别名: N-(5-amino-2-methoxyphenyl)acetamide；3-acetamido-4-methoxyaniline；2-acetamino-4-aminoanisol；acetic acid-(5-amino-2-methoxy-anilide)；6-Methoxy-N¹-acetyl-m-phenylendiamin；Essigsaeure-(5-amino-2-methoxy-anilid)
• CAS: 64353-88-4
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD00466048
• 分子量: 180.206
• InChiKey: NHHJPLIBPNEMHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(5-氨基-2-甲氧基苯基)乙酰胺 在 三氯氧磷 作用下， 生成 7-Acetylamino-4-chloro-6-methoxy-quinoline-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Quinoline-Carboxylic acids are potent inhibitors that inhibit the binding of insulin-Like growth factor (IGF) to IGF-Binding proteins

  摘要：

  4-Benzylquinolines 5, based on a series of isoquinolines 1, were prepared and tested as inhibitors of the IGF/IGFBP-3 complex based on their ability to displace IGF-I from its binding to IGF-binding protein-3. SAR studies on the 6,7-dihydroxy moiety of the quinoline 5a showed that the catecol moiety could be replaced with other functional groups. Computational modeling of the 5a/mini-IGFBP-5 complex revealed the possible binding site of 5a on IGFBP-5. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00322-6
• 作为产物：
  描述：

  N-(2-甲氧基-5-硝基苯基)-乙酰胺 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以97%的产率得到N-(5-氨基-2-甲氧基苯基)乙酰胺
  参考文献：
  名称：

  稠合喹啉衍生物的合成及其抗肿瘤活性。IV。新型的11-氨基吲哚并[3,2-b]喹啉。

  摘要：

  制备具有多种胺部分的吲哚并[3,2-b]喹啉衍生物（1），并评估了其对小鼠P388白血病的抗肿瘤活性，目的是了解胺部分在抗肿瘤活性和抗肿瘤作用中的作用。寻找有效的胺部分。在苯基与氨基或甲磺酰胺基之间引入亚甲基导致活性降低或丧失。

  DOI：

  10.1248/cpb.45.406

文献信息

• Tricyclic protein kinase inhibitors
  申请人：American Home Products Corporation

  公开号：US20030065180A1

  公开（公告）日：2003-04-03

  This invention provides compounds of Formula (I), 1 where A″, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

  这项发明提供了Formula (I)的化合物， 其中A″、Z、X和n的定义如下，或其药学上可接受的盐，这些化合物可用作抗肿瘤剂，并用于多囊肾病的治疗。
• 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
  申请人：American Home Products Corporation

  公开号：US20020026052A1

  公开（公告）日：2002-02-28

  This invention provides compounds of Formula (I), having the structure 1 where T, Z, X, A, R 1 , R 2a , R 2b , R 2c , R 3 , R 4 , and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

  这项发明提供了具有结构的化合物（I）的公式， 其中T、Z、X、A、R 1 、R 2a 、R 2b 、R 2c 、R 3 、R 4 和n在此处定义，或其药学上可接受的盐，这些化合物可用作抗肿瘤药物，并用于骨质疏松症和多囊肾病的治疗。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Non-fluorescent quencher compounds and biomolecular assays
  申请人：——

  公开号：US20030082547A1

  公开（公告）日：2003-05-01

  Bis-diazo,triaryl and aryldiazo-N-arylphenazonium quencher moieties, substituted with electron-withdrawing and electron-donating substituents which induce polarity in the delocalized aryl/diazo ring systems, are useful as labels when attached to biomolecules such as polynucleotides, nucleosides, nucleotides, and polypeptides. The quencher moieties are non-fluorescent and accept energy from fluorescent reporter labels by any energy-transfer mechanism, such as FRET. Fluorescence quencher compositions are useful in preparing quencher labelled biomolecules for various molecular biology assays based on fluorescence detection. 1

  双重重氮基、三芳基和芳基重氮-N-芳基苯酚盐猝灭基团，通过带电子吸引和电子给予取代基团引起芳基/重氮环系统极性，当连接到生物分子如多核苷酸、核苷、核苷酸和多肽时，可作为标签。这些猝灭基团是非荧光的，并通过任何能量转移机制（如FRET）从荧光报告标签吸收能量。荧光猝灭剂组合物在制备带有猝灭剂标记的生物分子，用于基于荧光检测的各种分子生物学分析中，非常有用。